ONO Pharmaceutical Co. Ltd.

12/25/2024 | Press release | Distributed by Public on 12/24/2024 22:02

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite[...]

 This material is intended to notify the press release issued on December 23 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.